1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Rain Oncology's 1-Year ROIIC % for the quarter that ended in Sep. 2023 was -99.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Rain Oncology's 1-Year ROIIC % or its related term are showing as below:
RAIN's 1-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -4.935
vs RAIN: -99.55
Rain Oncology 1-Year ROIIC % Historical Data
The historical data trend for Rain Oncology's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rain Oncology's 1-Year ROIIC %
For the Biotechnology subindustry, Rain Oncology's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rain Oncology's 1-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rain Oncology's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Rain Oncology's 1-Year ROIIC % falls into.
Rain Oncology 1-Year ROIIC % Calculation
Rain Oncology's 1-Year ROIIC % for the quarter that ended in Sep. 2023 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -73.7744 (Sep. 2023) - -71.656 (Sep. 2022) )
/
( 3.181 (Sep. 2023) - 1.053 (Sep. 2022) )
=
-2.1184
/
2.128
=
-99.55%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Rain Oncology 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Rain Oncology's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rain Oncology (Rain Oncology) Business Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your 